Menu Close
Headshot

Sally (Ping) Zhang

Executive Director, Head of R&D Quality Assurance APAC AstraZeneca

Sally has more than 18-year work experience in pharmaceutical drug development industry, including clinical operation, global quality assurance and leadership roles at AZ, Pfizer and CStone pharmaceutical.

She is now leading the R&D Quality Assurance team of APAC at AZ. Sally was selected as IFPMA (International Federation of Pharmaceutical Manufacturers amp; Associations) lead expert in 2019, since then, she has been working in global ICH Expert Working Group for ICH E6 revisions and related stakeholder engagement activities.

Sally used to be an ENT doctor before joining industry, she holds Master’s degree in clinical medicine, she graduated from Huaxi Medical Center of Sichuan University, under a partnership with Dalhousie University of Canada.

See Sally (Ping) Zhang at this event

  • Day 4 Friday 6 December

Advancing clinical trials: The impact of E6(R3) guideline

Session objectives:

  • Comprehend E6(R3) Guideline Revisions: key updates in E6(R3) and their significance for enhancing clinical trial practices and aligning with international standards.
  • Analyze Regulatory Preparations: how different regulatory authorities are preparing for the implementation of E6(R3).
  • Explore Data Integration: Consider the impact of E6(R3) on the use of Real-World Data (RWD) and Real-World Evidence (RWE), including the associated challenges and opportunities.

Speakers